111In-labelled somatostatin analogues in a rat tumour model: Somatostatin receptor status and effects of peptide receptor radionuclide therapy

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 32, Issue 11, 2005, Pages 1288-1295

  Capello, Astrid ^a   Krenning, Eric ^a   Bernard, Bert ^a   Reubi, Jean Claude ^b   Breeman, Wout ^a   De Jong, Marion ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

INDIUM 111; OCTREOTIDE PENTETIC ACID IN 111; PEPTIDE; RADIOPHARMACEUTICAL AGENT; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR; SOMATOSTATIN RECEPTOR 2; UNCLASSIFIED DRUG; 111IN OCTREOTIDE, DTPA(0); 111IN-OCTREOTIDE, DTPA(0)-; DIAGNOSTIC AGENT; DRUG DERIVATIVE; OCTREOTIDE; PENTETIC ACID; TUMOR MARKER;

ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ISOTOPE LABELING; MALE; NONHUMAN; PANCREAS TUMOR; PROTEIN EXPRESSION; RADIOISOTOPE THERAPY; RAT; RECEPTOR DENSITY; STATISTICAL SIGNIFICANCE; TUMOR CELL; TUMOR GROWTH; TUMOR MODEL; TUMOR VOLUME; ANIMAL; BODY WEIGHT; LEWIS RAT; METABOLISM; RADIATION DOSE; RADIATION EXPOSURE; RADIATION RESPONSE; SCINTISCANNING; SURVIVAL RATE; TISSUE DISTRIBUTION; TREATMENT OUTCOME; TUMOR CELL LINE;

ANIMALS; BODY WEIGHT; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, RADIATION; MALE; OCTREOTIDE; PANCREATIC NEOPLASMS; PENTETIC ACID; RADIOPHARMACEUTICALS; RADIOTHERAPY DOSAGE; RATS; RATS, INBRED LEW; RECEPTORS, SOMATOSTATIN; SURVIVAL RATE; TISSUE DISTRIBUTION; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 27744464045     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-005-1877-x     Document Type: Article

References (29)

1. Bell GI, Reisine T. Molecular biology of somatostatin receptors. Trends Neurosci 1993;16:34-8
2. Yamada Y, Kagimoto S, Kubota A, Yasuda K, Masuda K, Someya Y, et al. Cloning, functional expression and pharmacological characterization of a fourth (hSSTR4) and a fifth (hSSTR5) human somatostatin receptor subtype. Biochem Biophys Res Commun 1993;195:844-52
3. Kubota A, Yamada Y, Kagimoto S, Shimatsu A, Imamura M, Tsuda K, et al. Identification of somatostatin receptor subtypes and an implication for the efficacy of somatostatin analogue SMS 201-995 in treatment of human endocrine tumors. J Clin Invest 1994;93:1321-5
4. Reisine T, Bell GI. Molecular properties of somatostatin receptors. Neuroscience 1995;67:777-90
5. Patel YC, Greenwood M, Panetta R, Hukovic N, Grigorakis S, Robertson LA, et al. Molecular biology of somatostatin receptor subtypes. Metabolism 1996;45:31-8
6. 111In-labeled somatostatin analogues for tumor scintigraphy and radionuclide therapy. Cancer Res 1998;58:437-41
7. 3]-octreotide: the Rotterdam experience with more than 1,000 patients. Eur J Nucl Med 1993;20:716-31
8. Krenning EP, Kwekkeboom DJ, Pauwels S, Kvols LK, Reubi JC. Somatostatin receptor scintigraphy. In: Freeman LM, editor. Nuclear medicine annual. New York: Raven Press; 1995. p. 1-50
9. 3H. Nuclear versus cytoplasmic radiation effects in murine L1210 leukaemia. Int J Radiat Biol Relat Stud Phys Chem Med 1975;28:225-41
10. 125I-labeled DNA-binding compound that induces double-stranded DNA breaks. Cancer Res 1979;39:3244-7
11. 0]octreotide. J Nucl Med 2003;44:98-104
12. 1-octreetide in midgut carcinoid syndrome. J Nucl Med 1996;37:1519-21
13. McCarthy KE, Lemen L, Espenan G, Woltering EA, Nelson J, Cronin M, et al. Dose-escalation of indium-111 pentetreotide (SomatotherTM): toxicity and clinical response. Clin Nucl Med 1999;24:213
14. Valkema R, De Jong M, Bakker WH, Breeman WA, Kooij PP, Lugtenburg PJ, et al. Phase I study of peptide receptor radionuclide therapy with [In- DTPA]octreotide: the Rotterdam experience. Semin Nucl Med 2002;32:110-22
15. Slooter GD, Breeman WA, Marquet RL, Krenning EP, van Eijck CH. Anti-proliferative effect of radiolabelled octreotide in a metastases model in rat liver. Int J Cancer 1999;81:767-71
16. 1]- octreotide for detection of somatostatin receptor-positive tumors in rats. Life Sci 1991;49:1593-601
17. Green S, Weiss GR. Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Invest New Drugs 1992;10:239-53
18. Stabin MG, Konijnenberg MW Re-evaluation of absorbed fractions for photons and electrons in spheres of various sizes. J Nucl Med 2000;41:149-60
19. 177Lu. J Nucl Med 2004;45:1260-9
20. 1-octreotide. J Nucl Med 1996;37:2002-6
21. 3]octreotide: peptides for somatostatin receptor-targeted scintigraphy and radionuclide therapy. Nucl Med Commun 1998;19:283-8
22. Duncan JR, Stephenson MT, Wu HP, Anderson CJ. Indium-111- diethylenetriaminepentaacetic acid-octreotide is delivered in vivo to pancreatic, tumor cell, renal, and hepatocyte lysosomes. Cancer Res 1997;57:659-71
23. 3]octreotide is dependent on the peptide amount. Eur J Nucl Med 1999;26:693-8
24. 3]octreotate for somatostatin receptor-targeted radionuclide therapy. Int J Cancer 2001;92:628-33
25. 3] octreotide radionuclide therapy in a transplantable rat tumor model is dependent on tumor size. J Nucl Med 2001;42:1841-6
26. O'Donoghue JA, Bardies M, Wheldon TE. Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides. J Nucl Med 1995;36:1902-9
27. Jain RK. Transport of molecules, particles, and cells in solid tumors. Annu Rev Biomed Eng 1999;1:241-63
28. Béhé M, Püsken M, Henzel M, Gross M, Reitz I, Engelhart-Cabillic E, et al. Upregulation of gastrin and somatostatin receptor after irradiation. Eur J Nucl Med Mol Imaging 2003;30:S218
29. Béhé M, Koller S, Püsken M, Gross M, Alfke H, Keil B, et al. Irradiation-induced upregulation of somatostatin and gastrin receptors in vitro and in vivo. Eur J Nucl Med Mol Imaging 2004;31:S237-8